XTL Biopharmaceuticals Ltd.

Tel Aviv Stock Exchange XTLB.TA

XTL Biopharmaceuticals Ltd. EBITDA Margin for the year ending December 31, 2023

XTL Biopharmaceuticals Ltd. EBITDA Margin is NA for the year ending December 31, 2023. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.

Key data

Date	EBITDA Margin	EBIT Margin	Depreciation and Amortization	EBIT

Tel Aviv Stock Exchange: XTLB.TA

XTL Biopharmaceuticals Ltd.

CEO	Mr. Shlomo Spokone Shalev
IPO Date	Aug. 30, 2005
Location	Israel
Headquarters	5 Badner Street
Employees	8
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. The company's lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.

Key trends

Past 5 years